Common clinical pattern of antineutrophil cytoplasmic antibody -associated vasculitis

References

1. 1.↵
   1. Kronbichler A,
   2. Lee KH,
   3. Denicolo S,
   4. Choi D,
   5. Lee H,
   6. Ahn D, et al.

   Immunopathogenesis of ANCA-associated vasculitis. Int J Mol Sci 2020; 21:7319.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Lenka B,
   2. Zdenka H,
   3. Eva H

   . Pathophysiology of ANCA-associated vasculitis. Cesk Patol 2020; 56: 65–67.

   OpenUrl
3. 3.↵
   1. Mohammad AJ

   . An update on the epidemiology of ANCA-associated vasculitis. Rheumatology (Oxford) 2020; 59: 42–50.

   OpenUrl
4. 4.↵
   1. Alahmari H,
   2. Daajani HA,
   3. Alsayed F,
   4. Alrashid A

   . ANCA-associated vasculitis clinical presentation and clinical predictors of relapse in Saudi Arabia. Open Access Rheumatol 2021; 13: 213–220.

   OpenUrl
5. 5.↵
   1. Leacy E,
   2. Brady G,
   3. Little MA

   . Pathogenesis of ANCA-associated vasculitis: an emerging role for immunometabolism. Rheumatology (Oxford) 2020; 59: 33–41.

   OpenUrl
6. 6.↵
   1. Chen Z,
   2. Lin L,
   3. Yang W,
   4. Chen N,
   5. Lin Y

   . Clinical characteristics and prognostic risk factors of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). Int Immunopharmacol 2020; 87:106819.

   OpenUrl
7. 7.↵
   1. Mahr A,
   2. Specks U,
   3. Jayne D

   . Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology (Oxford) 2019; 58:1707–1709.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Samoreau C,
   2. Piccoli GB,
   3. Martin C,
   4. Gatault P,
   5. Vinatier E,
   6. Bridoux F, et al.

   Association between kinetic of Anti-Neutrophil Cytoplasmic Antibody (ANCA), renal survival and relapse risk in ANCA-glomerulonephritis. Nephrol Dial Transplant 2022; 240.
9. 9.↵
   1. Kitching AR,
   2. Anders HJ,
   3. Basu N,
   4. Brouwer E,
   5. Gordon J,
   6. Jayne DR, et al.

   ANCA-associated vasculitis. Nat Rev Dis Primers 2020; 6: 71.

   OpenUrl
10. 10.
    1. Pimentel-Quiroz VR,
    2. Sánchez-Torres A,
    3. Acevedo-Vásquez E,
    4. Gamboa-Cárdenas RV,
    5. Reátegui-Sokolova C,
    6. Medina-Chinchón M, et al.

    Demographic and clinical features of anca-associated vasculitides in a peruvian tertiary center. J Clin Rheumatol 2021; 27: S246–S251.

    OpenUrl
11. 11.↵
    1. Matsumoto K,
    2. Suzuki K,
    3. Yoshimoto K,
    4. Seki N,
    5. Tsujimoto H,
    6. Chiba K, et al.

    Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. Rheumatology (Oxford) 2020; 59: 545–553.

    OpenUrl
12. 12.↵
    1. Pu L,
    2. Li GS,
    3. Zou YR,
    4. Zhang P,
    5. Wang L

    . Clinical predictors of outcome in patients with anti-neutrophil cytoplasmic autoantibody-related renal vasculitis: experiences from a single-center. Chin Med J 2017; 130: 899–905.

    OpenUrl
13. 13.↵
    1. Walsh M,
    2. Merkel PA,
    3. Peh CA,
    4. Szpirt WM,
    5. Puéchal X,
    6. Fujimoto S, et al.

    Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 2020; 382: 622–631.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Shi L

    . Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int 2017; 37: 1779–1788.

    OpenUrl
15. 15.↵
    1. Unizony S,
    2. Villarreal M,
    3. Miloslavsky EM,
    4. Lu N,
    5. Merkel PA,
    6. Spiera R, et al.

    Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 2016; 75: 1166–1169.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Watts R,
    2. Lane S,
    3. Hanslik T,
    4. Hauser T,
    5. Hellmich B,
    6. Koldingsnes W, et al.

    Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222–227.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Yates M,
    2. Watts R

    . ANCA-associated vasculitis. Clin Med (Lond) 2017; 17: 60–64.

    OpenUrl
18. 18.↵
    1. Arzoun H,
    2. Srinivasan M,
    3. Thangaraj SR,
    4. Thomas SS,
    5. Yarema A,
    6. Lee B, et al.

    Recent advancements in the management of anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review. Cureus 2022; 14.
19. 19.↵
    1. Almaani S,
    2. Fussner LA,
    3. Brodsky S,
    4. Meara AS,
    5. Jayne D

    . ANCA-associated vasculitis: an update. J Clin Med 2021; 10:1446.

    OpenUrl
20. 20.↵
    1. Al Arfaj AS,
    2. Khalil N

    . ANCA associated vasculitis in patients from Saudi Arabia. Pak J Med Sci 2018; 34: 88–93.

    OpenUrl
21. 21.↵
    1. Zhang W,
    2. Zhou G,
    3. Shi Q,
    4. Zhang X,
    5. Zeng XF,
    6. Zhang FC

    . Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 2009; 27: S65–S69.

    OpenUrlPubMed
22. 22.↵
    1. Krasselt ML,
    2. Holle JU

    . ANCA-assoziierte Vaskulitis [ANCA-associated vasculitis]. Inn Med (Heidelb) 2022; 63:947–960.

    OpenUrl